EUVIMEDEUVIMED entdecken
Open Access

Therapeutic implications of targeting cancer testis antigen MAGEA1 in cervical cancer

Ayoung Kim, Jina Kim, Woori Kwak, Kyumin Mo, Soohyun Choe, Minyeong Jeon, Jisun Lee, Jun-Won Yun, Hyunho Yoon

International Journal of Oncology · 2026

DOI: 10.3892/ijo.2026.5870 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Oncology, 2026. Verfasst von Ayoung Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi 14662, Republic of Korea. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Melanoma-Specific Antigens, Biomarkers, Tumor, Antigens, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MAGE family member A1 (MAGEA1), a cancer‑testis antigen (CTA), is aberrantly expressed in several malignancies such as lung and liver cancers. However, its role in cervical cancer remains to be elucidated. The present study investigated the functional significance and therapeutic potential of MAGEA1 in cervical cancer using lentiviral short hairpin RNA‑mediated knockdown, a series of functional assays, RNA sequencing (RNA‑seq), and nude mouse xenograft models. It was found that MAGEA1 was upregulated in cervical cancer cells and its knockdown substantially suppressed cell proliferation, migration, invasion, and in vivo tumor growth. RNA‑seq analysis further revealed that MAGEA1 silencing altered pathways related to apoptosis, DNA repair, and metabolism. Moreover, MAGEA1 knockdown enhanced chemosensitivity, indicating a potential role in mediating drug resistance. Collectively, the findings identified MAGEA1 as a key oncogenic driver in cervical cancer and highlighted its promise as both a prognostic biomarker and a therapeutic target, offering novel avenues for personalized treatment strategies in cervical cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsMelanoma-Specific AntigensBiomarkers, TumorAntigens, NeoplasmHumansFemaleAnimalsMiceCell ProliferationGene Expression Regulation, NeoplasticXenograft Model Antitumor AssaysCell Line, TumorMice, NudeCell MovementApoptosisRNA, Small InterferingGene Knockdown TechniquesDrug Resistance, Neoplasm

Stichwörter der Autor:innen

MAGE family member A1biomarkercancer testis antigencervical canceroncogene

Substanzen

MAGEA1 protein, humanMelanoma-Specific AntigensBiomarkers, TumorRNA, Small InterferingAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi 14662, Republic of Korea.
  • Laboratory of Veterinary Toxicology, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul 08826, Republic of Korea.

Zitieren

APA

Kim, A., Kim, J., Kwak, W., Mo, K., Choe, S., Jeon, M., Lee, J., Yun, J. W., & Yoon, H. (2026). Therapeutic implications of targeting cancer testis antigen MAGEA1 in cervical cancer. International Journal of Oncology. https://doi.org/10.3892/ijo.2026.5870

Vancouver

Kim A, Kim J, Kwak W, Mo K, Choe S, Jeon M, et al. Therapeutic implications of targeting cancer testis antigen MAGEA1 in cervical cancer. International Journal of Oncology. 2026. doi:10.3892/ijo.2026.5870

BibTeX
@article{Kim2026,
  author = {Kim, Ayoung and Kim, Jina and Kwak, Woori and Mo, Kyumin and Choe, Soohyun and Jeon, Minyeong and Lee, Jisun and Yun, Jun-Won and Yoon, Hyunho},
  title = {Therapeutic implications of targeting cancer testis antigen MAGEA1 in cervical cancer},
  journal = {International Journal of Oncology},
  year = {2026},
  doi = {10.3892/ijo.2026.5870}
}
Kostenlos starten →